A 21-year-old man was admitted to the hospital with severe chest pain. Apart from atopic asthma in childhood, pollen and pet allergy, and appendectomy a few years ago, his past medical history was unremarkable, and he did not have a symptomatic COVID-19 infection in the past. He worked physically as a warehouse worker and trained regularly Brazilian Jiu-Jitsu without any health problems. The family history was negative for cardiovascular disease. Three days before hospitalization, the patient received the first dose of mRNA COVID-19 vaccination (Comirnaty, Pfizer). Apart from mild muscle pain at the site of vaccine administration, he did not experience any other symptoms during the first two days. On admission day, he woke up at night due to a tight and squeezing sensation in his chest, which he rated as 8 points in the 0–10 Numeric Rating Scale used to estimate the intensity of pain. The chest discomfort lasted about 3 hours despite taking a painkiller; it resolved spontaneously and did not return later.

On admission to the hospital, the patient was hemodynamically stable. Electrocardiography showed sinus rhythm at a heart rate of 50 beats per minute, an incomplete right bundle branch block, Q wave and ST-segment elevation less than 1 mm in leads II, III and aVF, negative T-wave in lead V1 and patterns of precordial early repolarization (Figure 1A). Blood tests demonstrated elevated levels of high-sensitive cardiac troponin I (6490––6559 pg/ml; reference range< 34 pg/ml), N-terminal fragment of the prohormone brain natriuretic peptide (337 pg/ml; reference range< 125 pg/ml), and C-reactive protein (82 mg/l; reference range< 5 mg/l). Echocardiography demonstrated a normal-sized, non-hypertrophic left ventricle with normal ejection fraction (biplane, 58%) and